These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28705532)

  • 1. Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments.
    Koola MM; Sklar J; Davis W; Nikiforuk A; Meissen JK; Sawant-Basak A; Aaronson ST; Kozak R
    Schizophr Res; 2018 Mar; 193():459-460. PubMed ID: 28705532
    [No Abstract]   [Full Text] [Related]  

  • 2. Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement.
    Koola MM
    Prim Care Companion CNS Disord; 2018 Mar; 20(2):. PubMed ID: 29570959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.
    Peters O; Lorenz D; Fesche A; Schmidtke K; Hüll M; Perneczky R; Rüther E; Möller HJ; Jessen F; Maier W; Kornhuber J; Jahn H; Luckhaus C; Gertz HJ; Schröder J; Pantel J; Teipel S; Wellek S; Frölich L; Heuser I
    J Nutr Health Aging; 2012; 16(6):544-8. PubMed ID: 22659994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.
    Koola MM; Buchanan RW; Pillai A; Aitchison KJ; Weinberger DR; Aaronson ST; Dickerson FB
    Schizophr Res; 2014 Aug; 157(1-3):84-9. PubMed ID: 24878431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine.
    Koola MM
    Schizophr Res Cogn; 2016 Jun; 4():4-9. PubMed ID: 27069875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
    Matsuzono K; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 45(3):771-80. PubMed ID: 25624417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease.
    Formiga F; Fort I; Robles MJ; Rodriguez D; Regalado P
    Dement Geriatr Cogn Disord; 2010; 29(3):198-203. PubMed ID: 20332637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia.
    Koola MM
    Mol Neuropsychiatry; 2018 Dec; 4(3):134-148. PubMed ID: 30643787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement.
    Koola MM; Looney SW; Hong H; Pillai A; Hou W
    Psychiatry Res; 2020 Sep; 291():113285. PubMed ID: 32763546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of galantamine on psychopathology in chronic stable schizophrenia.
    Conley RR; Boggs DL; Kelly DL; McMahon RP; Dickinson D; Feldman S; Ball MP; Buchanan RW
    Clin Neuropharmacol; 2009; 32(2):69-74. PubMed ID: 18978489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia.
    Koola MM; Praharaj SK; Pillai A
    Curr Behav Neurosci Rep; 2019 Jun; 6(2):37-50. PubMed ID: 32601581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model.
    Van Dam D; De Deyn PP
    Eur Neuropsychopharmacol; 2006 Jan; 16(1):59-69. PubMed ID: 16095884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight-loss associated with anti-dementia drugs in a patient with Parkinson's disease.
    Gallini A; Sommet A; Salandini AM; Veyssière P; Montastruc JL; Montastruc JL
    Mov Disord; 2007 Oct; 22(13):1980-1. PubMed ID: 17657810
    [No Abstract]   [Full Text] [Related]  

  • 16. Galantamine and memantine combination for cognition: Enough or more than enough to translate from murines and macaques to men with schizophrenia?
    Koola MM
    Asian J Psychiatr; 2019 Apr; 42():115-118. PubMed ID: 29150389
    [No Abstract]   [Full Text] [Related]  

  • 17. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
    Lindenmayer JP; Khan A
    Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study.
    Veerman SR; Schulte PF; Deijen JB; de Haan L
    Psychol Med; 2017 Jan; 47(2):363-375. PubMed ID: 27776560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
    Sevilla C; Jiménez Caballero PE; Alfonso V; González-Adalid M
    Dement Geriatr Cogn Disord; 2009; 28(3):196-205. PubMed ID: 19738386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.
    Buchanan RW; Kelly DL; Weiner E; Gold JM; Strauss GP; Koola MM; McMahon RP; Carpenter WT
    J Clin Psychopharmacol; 2017 Aug; 37(4):394-400. PubMed ID: 28590362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.